Private equity firms eye $3B deal for vaccine maker Bavarian Nordicnews2025-07-28T12:29:08+00:00July 28th, 2025|Endpoints News|
Shanghai biotech VelaVigo snags $60M after landing two licensing dealsnews2025-07-28T11:14:08+00:00July 28th, 2025|Endpoints News|
Recognify’s schizophrenia drug fails mid-stage test, backer atai’s stock dipsnews2025-07-28T11:08:08+00:00July 28th, 2025|Endpoints News|
Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Rochenews2025-07-28T10:00:40+00:00July 28th, 2025|Endpoints News|
GSK sends $500M upfront to Hengrui in broad deal with China’s leading pharmanews2025-07-28T08:41:25+00:00July 28th, 2025|Endpoints News|
Sarepta fallout continues; MAHA is angry as Loomer points fingers; A CAR-T week in biotech; and morenews2025-07-26T10:00:41+00:00July 26th, 2025|Endpoints News|
FDA investigates death of boy who got Elevidys, Roche says death unrelated to therapynews2025-07-26T09:32:16+00:00July 26th, 2025|Endpoints News|
FDA delays decision date on Bayer’s hot flash drugnews2025-07-25T19:20:37+00:00July 25th, 2025|Endpoints News|
FDA developing new flu vaccine framework to tackle ‘problems,’ senior official saysnews2025-07-25T19:08:08+00:00July 25th, 2025|Endpoints News|
CHMP backs Lilly’s Alzheimer’s drug in certain patients, Gilead’s twice-yearly HIV prevention shot, among othersnews2025-07-25T15:17:24+00:00July 25th, 2025|Endpoints News|
